ÂÜÀòÂÒÂ×

Analeah Heidt is a seasoned professional in the field of biochemistry and molecular biology, currently serving as Chief Scientific Officer at Enlaza Therapeutics since August 2021. Prior experience includes notable roles at Inhibrx, Inc., where Analeah held titles such as Executive Vice President, Translational Research, and Vice President, Translational Research from June 2017 to August 2021. Analeah's career began at GNF, progressing from Postdoc to Senior Research Investigator I from August 2006 to June 2017. Analeah holds a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco, and a Bachelor's Degree in Biology and Chemistry from Claremont McKenna College.